Xynomic Pharmaceuticals Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
12
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Xynomic Pharmaceuticals General Information
Description
Developer of anti-tumor drugs aims to build a clinical and pre-clinical stage oncology pipeline targeting cancers. The company focuses on in-licensing, developing, and commercializing oncology drug candidates, enabling the company to develop drugs in a cost and time-efficient manner.
Contact Information
Website
www.xynomicpharma.com(Operating Subsidiary)
Corporate Office
- 13029 Danielson Street
- Suite 120
- Poway, CA 92064
- United States
Corporate Office
- 13029 Danielson Street
- Suite 120
- Poway, CA 92064
- United States
Xynomic Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | 17-Jun-2021 | Completed | Generating Revenue | |||
| 5. PIPE | 14-May-2019 | Completed | Pre-Clinical Trials | |||
| 4. Reverse Merger | 14-May-2019 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series B) | 04-Jun-2018 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 01-Feb-2017 | $4.3M | $4.8M | Completed | Startup | |
| 1. Seed Round | $500K | $500K | Completed | Startup |
Xynomic Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Angel | 23,435,379 | $0.000100 | 8% | $0.02 | $0.02 | 1x | $0.02 | 23.8% |
Xynomic Pharmaceuticals Comparisons
Industry
Financing
Details
Xynomic Pharmaceuticals Competitors (112)
One of Xynomic Pharmaceuticals’s 112 competitors is Immune-Onc Therapeutics, a Venture Capital-Backed company based in Palo Alto, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immune-Onc Therapeutics | Venture Capital-Backed | Palo Alto, CA | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| Sygnature Discovery | Private Equity-Backed | Nottingham, United Kingdom | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH | ||||
| Lite Strategy | Corporation | San Diego, CA |
Xynomic Pharmaceuticals Patents
Xynomic Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2021501199-A | Crystalline salt of b-raf kinase inhibitor | Active | 26-Oct-2017 | ||
| JP-2023062074-A | Crystalline salt of b-raf kinase inhibitor | Pending | 26-Oct-2017 | ||
| JP-7230041-B2 | Crystalline salt of b-raf kinase inhibitor | Active | 26-Oct-2017 | ||
| AU-2018355528-A1 | Crystalline salts of a b-raf kinase inhibitor | Active | 26-Oct-2017 | ||
| AU-2018355528-B2 | Crystalline salts of a b-raf kinase inhibitor | Active | 26-Oct-2017 | C07D471/04 |
Xynomic Pharmaceuticals Signals
Xynomic Pharmaceuticals Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bison Capital Acquisition | Special Purpose Acquisition Company (SPAC) | Minority | ||
| EarlyBirdCapital | Investment Bank | Minority | ||
| Hakim Unique | Corporation | Minority | ||
| Northern Light Venture Capital | Venture Capital | Minority | ||
| Prosperico Ventures | Venture Capital | Minority |
Xynomic Pharmaceuticals Investments & Acquisitions (2)
Xynomic Pharmaceuticals’s most recent deal was a Merger/Acquisition with Bison Capital Acquisition. The deal was made on 15-May-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Bison Capital Acquisition | 15-May-2019 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) | ||
| Boehringer Ingelheim (BI 882370 Global rights) | 30-Oct-2017 | Corporate Asset Purchase | Buildings and Property |
Xynomic Pharmaceuticals FAQs
-
When was Xynomic Pharmaceuticals founded?
Xynomic Pharmaceuticals was founded in 2016.
-
Where is Xynomic Pharmaceuticals headquartered?
Xynomic Pharmaceuticals is headquartered in Poway, CA.
-
What is the size of Xynomic Pharmaceuticals?
Xynomic Pharmaceuticals has 12 total employees.
-
What industry is Xynomic Pharmaceuticals in?
Xynomic Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Xynomic Pharmaceuticals a private or public company?
Xynomic Pharmaceuticals is a Private company.
-
What is Xynomic Pharmaceuticals’s current revenue?
The current revenue for Xynomic Pharmaceuticals is .
-
How much funding has Xynomic Pharmaceuticals raised over time?
Xynomic Pharmaceuticals has raised $21.8M.
-
Who are Xynomic Pharmaceuticals’s investors?
Bison Capital Acquisition, EarlyBirdCapital, Hakim Unique, Northern Light Venture Capital, and Prosperico Ventures are 5 of 7 investors who have invested in Xynomic Pharmaceuticals.
-
Who are Xynomic Pharmaceuticals’s competitors?
Immune-Onc Therapeutics, Iovance Biotherapeutics, Sygnature Discovery, Adimab, and Lite Strategy are some of the 112 competitors of Xynomic Pharmaceuticals.
-
When was Xynomic Pharmaceuticals acquired?
Xynomic Pharmaceuticals was acquired on 17-Jun-2021.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process